Graft-versus-host Disease
📧 Sign up to get email alerts when something new happens for Graft-versus-host Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-07-19Clinical Trial Update: Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole [Phase 2]
A Phase 2 clinical trial evaluating peripheral blood stem cell transplantation from family haploidentical donors in patients with myelodyspl…
-
CLINICAL_TRIALS trial_result · 2022-07-12Clinical Trial Update: Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD) [Phase 2]
Phase 2 trial of topical ruxolitinib for cutaneous chronic graft-versus-host disease has terminated; results were posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-07-06Clinical Trial Update: Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease [Phase 3]
A Phase 3 study of brimonidine tartrate nanoemulsion eye drops for ocular graft-versus-host disease has been terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2022-05-24Clinical Trial Update: Efficacy and Safety Study of ATG for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT [Phase 4]
Clinical trial update on ATG for prophylaxis of acute graft-versus-host disease in matched sibling donor peripheral blood stem cell transpla…
-
CLINICAL_TRIALS trial_result · 2022-05-17Clinical Trial Update: Maraviroc in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation [Phase 1, Phase 2]
Clinical trial updates on maraviroc for patients undergoing non-myeloablative allogeneic stem-cell transplantation (Phase 1/Phase 2).
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-05-11FDA Approved: IMBRUVICA — Supplemental Application (Pharmacyclics LLC)
FDA approved a supplemental application for IMBRUVICA (ibrutinib) from Pharmacyclics LLC.
-
FDA approval · 2022-05-11FDA Approved: IMBRUVICA — Supplemental Application (Pharmacyclics LLC)
FDA approves a supplemental application for IMBRUVICA (ibrutinib) submitted by Pharmacyclics LLC. The document indicates FDA approval of the…
-
CLINICAL_TRIALS trial_result · 2022-05-10Clinical Trial Update: MAP-guided Preemptive Therapy of aGvHD [Phase 2]
A Phase 2 clinical trial evaluating MAP-guided preemptive therapy for acute graft-versus-host disease (GVHD) following stem cell transplanta…
-
CLINICAL_TRIALS trial_result · 2022-05-09Clinical Trial Update: Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide [Phase 2]
Phase 2 trial investigating arsenic trioxide for treatment of chronic graft-versus-host disease has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2022-04-27Clinical Trial Update: Efficacy and Safety of Low-dose Ibrutinib and Itraconazole in Chronic Graft Versus Host Disease [Phase 2]
Phase 2 trial evaluating low-dose ibTrutinib and itraconazole for efficacy and safety in chronic graft-versus-host disease.
-
CLINICAL_TRIALS trial_result · 2022-04-20Clinical Trial Update: MTX and Steroid for III-IV aGVHD Treatment [Phase 2]
Phase 2 clinical trial update investigating methotrexate and steroid for treatment of acute graft-versus-host disease.
-
CLINICAL_TRIALS trial_result · 2022-04-15Clinical Trial Update: A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) [Phase 3]
Phase 3 REACH3 trial comparing ruxolitinib to best available therapy for steroid-refractory chronic graft-versus-host disease after allogene…
-
CLINICAL_TRIALS trial_result · 2022-03-17Clinical Trial Update: A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD) [Phase 3]
Phase 3 trial investigating remestemcel-L (ex vivo cultured mesenchymal stromal cells) for pediatric steroid-refractory acute GVHD; study co…
-
CLINICAL_TRIALS trial_result · 2022-03-16Clinical Trial Update: Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute GVHD [Phase 3]
Phase 3 safety follow-up study of remestemcel-L in pediatric patients with acute graft-versus-host disease that failed to respond to steroid…
-
CLINICAL_TRIALS trial_result · 2022-03-11Clinical Trial Update: A Prospective, Open Label, Dose-escalation, SAD/MAD, Multicenter, 24weeks, Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamics of Investigational Product (VM-001) in Patients With Graft-versus-host Disease(GvHD) [Phase 1, Phase 2]
A phase I/IIa open-label trial evaluating safety, tolerability, and pharmacodynamics of VM-001 in patients with graft-versus-host disease (G…
-
CLINICAL_TRIALS trial_result · 2022-03-02Clinical Trial Update: In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating in-vivo regulatory T cell enhancement using cyclophosphamide and sirolimus for graft-versus-host disea…
-
CLINICAL_TRIALS trial_result · 2022-02-22Clinical Trial Update: Efficacy and Safety Study of 4-Day ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT [Phase 2]
Phase 2 trial update evaluating a 4-day ATG regimen for prophylaxis of acute and chronic GVHD after matched sibling donor peripheral blood s…
-
CLINICAL_TRIALS trial_result · 2022-02-10Clinical Trial Update: Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD) [Phase 3]
Phase 3 trial update evaluating adult human mesenchymal stem cells for efficacy and safety in steroid-refractory acute graft-versus-host dis…
-
CLINICAL_TRIALS trial_result · 2022-02-10Clinical Trial Update: Dexamethasone to Prevent Oral Chronic Graft-versus-Host Disease [Phase 2]
Phase 2 trial assessing dexamethasone to prevent oral chronic graft-versus-host disease; study completed with results posted.
-
FDA approval · 2022-02-02FDA Approved: CYCLOSPORINE — Original Application (Mylan Pharmaceuticals Inc.)
The FDA approved Mylan Pharmaceuticals' original application for cyclosporine, a generic immunosuppressant product. This makes a generic cyc…
-
CLINICAL_TRIALS trial_result · 2022-01-31Clinical Trial Update: Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD) [Phase 2]
Phase 2 clinical trial update evaluating adult human mesenchymal stem cells for treating acute graft-versus-host disease (GVHD) has complete…
-
CLINICAL_TRIALS trial_result · 2022-01-19Clinical Trial Update: Efficacy and Safety of Prochymal® Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute Graft Versus Host Disease (GVHD) [Phase 3]
Phase 3 trial update evaluating Prochymal infusion with corticosteroids for newly diagnosed acute graft-versus-host disease; study completed…
-
CLINICAL_TRIALS trial_result · 2022-01-11Clinical Trial Update: Comparison of PT-Cy at a Dose of 25 mg/kg/Day and PT-Cy at a Dose of 50 mg/kg/Day in GVHD Prophylaxis [Phase 3]
Phase 3 trial comparing two doses of post-transplant cyclophosphamide (PT-Cy) for graft-versus-host disease prophylaxis; status not disclose…
-
CLINICAL_TRIALS withdrawal · 2022-01-05Clinical Trial Update: Evaluation of Dextenza in Patients With Ocular GVHD and Effects on Ocular Surface Disease Outcomes [Phase 4]
Phase 4 trial evaluating Dextenza for ocular GVHD was withdrawn.
-
CLINICAL_TRIALS trial_result · 2021-12-14Clinical Trial Update: Low Dose Ruxolitinib in Combination With Methylprednisolone [Phase 1, Phase 2]
Clinical trial update for low-dose ruxolitinib combined with methylprednisolone in Phase 1/2 for acute graft-versus-host disease and stem ce…